Targocid

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

Teicoplanin; Water for injections

Available from:

Sanofi-Aventis Australia Pty Ltd

Class:

Medicine Registered

Patient Information leaflet

TARGOCID
®

(TAR-GO-SID)
_teicoplanin (tee-co-plan-in)_
CONSUMER MEDICINE INFORMATION

WHAT IS IN THIS LEAFLET
This leaflet answers some common
questions about Targocid.
It does not contain all the available
information. It does not take the
place of talking to your doctor, or
pharmacist.
All medicines have risks and
benefits. Your doctor or pharmacist
has weighed the risks of you being
given this medicine against the
benefits they expect it will have.
IF YOU HAVE ANY CONCERNS ABOUT
BEING GIVEN THIS MEDICINE, ASK YOUR
DOCTOR OR PHARMACIST.
KEEP THIS LEAFLET. YOU MAY NEED TO
READ IT AGAIN.
WHAT TARGOCID IS USED
FOR
Targocid injection is an antibiotic. It
is used to kill bacteria responsible for
infections which can occur in your
blood, bones or joints. This antibiotic
is generally used when the bacteria
causing the infection are not
satisfactorily eliminated by other
antibiotics (eg penicillin) or when
patients may be allergic to other
antibiotics.
Your doctor, however, may prescribe
Targocid for another purpose.
ASK YOUR DOCTOR IF YOU HAVE ANY
QUESTIONS ABOUT WHY IT HAS BEEN
PRESCRIBED FOR YOU.
This medicine is only available with
a doctor's prescription.
There is no evidence that this
medicine is addictive.
BEFORE YOU ARE GIVEN IT
_WHEN YOU MUST NOT BE GIVEN_
_IT_
DO NOT RECEIVE TARGOCID IF YOU ARE
ALLERGIC TO IT OR ANY OF THE
INGREDIENTS LISTED AT THE END OF THIS
LEAFLET.
Some symptoms of an allergic
reaction include skin rash, itching,
shortness of breath or swelling of the
face, lips or tongue, which may cause
difficulty in swallowing or breathing.
DO NOT RECEIVE IT IF YOU ARE
PREGNANT OR INTEND TO BECOME
PREGNANT.
It may affect your developing baby if
you are given it during pregnancy.
DO NOT RECEIVE IT IF YOU ARE
BREASTFEEDING OR PLANNING TO
BREASTFEED.
It is not known whether Targocid
passes into breast milk.
DO NOT RECEIVE IT AFTER THE EXPIRY
DATE (EXP) PRINTED ON THE PACK OR
VIAL,
If you receive it after the expiry date
has passed, it may not work as well.
DO NOT RECEIVE IT IF THE PACKAGE

Summary of Product characteristics

Targocid PI 
15784v3.0 
1 

PRODUCT INFORMATION 
TARGOCID 
NAME OF THE MEDICINE 
NON-PROPRIETARY NAME 
teicoplanin 
DESCRIPTION 
Teicoplanin is a glycopeptide-antibiotic produced by _Actinoplanes
teichomyceticus_. It is 
presented as a sterile, pyrogen-free ivory white powder for
reconstitution with water for 
injection. It is freely soluble in water and on reconstitution gives a
clear solution. 
MICROBIOLOGY 
Teicoplanin is bactericidal or bacteriostatic on growing populations
of susceptible Gram-
positive organisms; depending on the sensitivity of the organism and
antibiotic 
concentration. 
Teicoplanin inhibits the growth of susceptible organisms by
interfering with cell-wall 
biosynthesis at a different site from that affected by 
β-lactams. Teicoplanin is therefore 
effective against staphylococci (including those resistant to
methicillin and other 
β-lactam 
antibiotics) and streptococci. 
Some cross-resistance is observed between teicoplanin and the
glycopeptide 
vancomycin.  
Teicoplanin has shown no cross-resistance to 
β-lactam antibiotics, macrolides, 
aminoglycosides, tetracycline, rifampicin or chloramphenicol. 
PHARMACOLOGY 
PHARMACOKINETICS 
In man, the plasma level profile after intravenous administration
indicates a biphasic 
distribution (with a rapid distribution phase having a
half-life of about 0.3 hours, followed 
by a more prolonged distribution phase having a half-life of 3
hours). At the end of the 
distribution phase, plasma levels and the subsequent
time-concentration curves, are 
identical following intramuscular or intravenous administration of
3 mg/kg dose. Following 
intramuscular injection bioavailability is 100%; average
peak plasma levels of 7.1 
μg/mL 
are achieved in 3-4 hours following a dose of 3 mg/kg. 
The elimination half-life is 70-100 hours. The apparent volume of
distribution at steady 
state is similar to total body water, i.e. 0.6 L/kg.  
Approximately 90-95 % of teicoplanin is bo